Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 8/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 6/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 5/20 | 1.00 |
| ▸ | ADORA2B | P29275 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.98 |
| ▸ | HTR2C | P28335 | 1/20 | 0.75 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29354999 | 1.00 | ADORA3 (1.00) | ADORA3ADORA2AADORA1ADORA2BMEN1 | |
| SCHEMBL16081269 | 1.00 | ADORA3 (1.00) | ADORA3ADORA2AADORA1ADORA2BMEN1 | |
| SCHEMBL120439 | 1.00 | ADORA3 (1.00) | ADORA3ADORA2AADORA1ADORA2BMEN1 | |
| SCHEMBL2461163 | 1.00 | ADORA3 (1.00) | ADORA3ADORA2AADORA1ADORA2BMEN1 | |
| SCHEMBL12264514 | 1.00 | ADORA3 (1.00) | ADORA3ADORA2AADORA1ADORA2BMEN1 | |
| SCHEMBL19807522 | 1.00 | ADORA3 (1.00) | ADORA3ADORA2AADORA1ADORA2BMEN1 | |
| SCHEMBL3950346 | 1.00 | ADORA3 (1.00) | ADORA3ADORA2AADORA1ADORA2BMEN1 | |
| SCHEMBL472609 | 1.00 | ADORA3 (1.00) | ADORA3ADORA2AADORA1ADORA2BMEN1 | |
| SCHEMBL9498481 | 0.99 | ADORA3 (0.98) | ADORA3ADORA2AADORA1ADORA2BMEN1 | |
| SCHEMBL4803030 | 0.99 | ADORA3 (0.98) | ADORA3ADORA2AADORA1ADORA2BMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013049725-A2 | METHODS OF USING ADENOSINE A1 RECEPTOR ACTIVATION FOR TREATING DEPRESSION | TUFTS UNIVERSITY (US) | 2013-04-04 | — | — | WO | claimed |
| CN-119365476-A | Cyclopentyl adenosine derivative and pharmaceutical application thereof | 上海森辉医药有限公司 | 2025-01-24 | — | — | CN | disclosed |
| US-20140241990-A1 | METHODS OF USING ADENOSINE A1 RECEPTOR ACTIVATION FOR TREATING DEPRESSION | TUFTS UNIVERSITY (US) | 2014-08-28 | — | — | US | disclosed |
| WO-2013049725-A2 | METHODS OF USING ADENOSINE A1 RECEPTOR ACTIVATION FOR TREATING DEPRESSION | TUFTS UNIVERSITY (US) | 2013-04-04 | — | — | WO | disclosed |
| EP-2555775-A1 | COMBINATION COMPOSITIONS OF ADENOSINE A1 AGONISTS AND CARBONIC ANHYDRASE INHIBITORS FOR REDUCING INTRAOCULAR PRESSURE | Inotek Pharmaceuticals Corporation (US) | 2013-02-13 | — | — | EP | disclosed |
| WO-2011116290-A1 | COMBINATION COMPOSITIONS OF ADENOSINE A1 AGONISTS AND CARBONIC ANHYDRASE INHIBITORS FOR REDUCING INTRAOCULAR PRESSURE | INOTEK PHARMACEUTICALS CORPORATION (US) | 2011-09-22 | — | — | WO | disclosed |
| US-20090156544-A1 | A1 ADENOSINE RECEPTOR AGONISTS | ELZEIN ELFATIH | 2009-06-18 | — | — | US | disclosed |
| US-7514417-B2 | A1 adenosine receptor agonists | CV THERAPEUTICS, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-7381714-B2 | A1 adenosine receptor agonists | CV THERAPEUTICS, INC. (US) | 2008-06-03 | — | — | US | disclosed |
| EP-1883646-A1 | A1 ADENOSINE RECEPTOR AGONISTS | CV THERAPEUTICS, INC. (US) | 2008-02-06 | — | — | EP | disclosed |
| EP-1881991-A1 | A1 ADENOSINE RECEPTOR AGONISTS | CV THERAPEUTICS, INC. (US) | 2008-01-30 | — | — | EP | disclosed |
| US-20060281705-A1 | A1 adenosine receptor agonists | CV THERAPEUTICS, INC. | 2006-12-14 | — | — | US | disclosed |
| US-20060276428-A1 | A1 adenosine receptor agonists | CV THERAPEUTICS, INC. | 2006-12-07 | — | — | US | disclosed |
| WO-2006125211-A1 | A1 ADENOSINE RECEPTOR AGONISTS | CV THERAPEUTICS, INC. (US) | 2006-11-23 | — | — | WO | disclosed |
| WO-2006125190-A1 | A1 ADENOSINE RECEPTOR AGONISTS | CV THERAPEUTICS, INC. (US) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156544-A1 | A1 ADENOSINE RECEPTOR AGONISTS | ADORA1, ADORA2A, ADORA3 | ADORA3 3/4885ADORA2A 2/4885ADORA1 1/4885 |
| US-20140241990-A1 | METHODS OF USING ADENOSINE A1 RECEPTOR ACTIVATION FOR TREATING DEPRESSION | ADORA2A, ADORA1, ADORA3 | ADORA3 3/4885ADORA2A 1/4885ADORA1 2/4885 |
| US-20060281705-A1 | A1 adenosine receptor agonists | ADORA1, ADORA2A, ADORA3 | ADORA3 3/4885ADORA2A 2/4885ADORA1 1/4885 |
| US-20060276428-A1 | A1 adenosine receptor agonists | ADORA1, ADORA2A, ADORA3 | ADORA3 3/4885ADORA2A 2/4885ADORA1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.